Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31702867 | 0.85 | CYP3A4 (0.46) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 | |
| SCHEMBL2028119 | 0.83 | RXRA (0.40) | CREBBPALDH1A1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL2022640 | 0.83 | GAA (0.45) | ALDH1A1KDM4EHSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL1504723 | 0.82 | NOTUM (0.42) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 | |
| SCHEMBL375200 | 0.80 | RORC (0.42) | CYP1A2RORCCYP2C9 | |
| SCHEMBL1504495 | 0.80 | TTR (0.46) | CREBBPCYP1A2RORCCYP2C9 | |
| SCHEMBL31702858 | 0.78 | CA1 (0.43) | ALDH1A1KDM4ESMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3305068 | 0.77 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 | |
| SCHEMBL146048 | 0.75 | KDM4E (0.56) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 | |
| SCHEMBL4246208 | 0.75 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDHSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-1810972-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-7968572-B2 | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| EP-2155683-B1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-7713998-B2 | Nitrogenous heterocyclic compound and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063104-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-1932840-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1810972-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265308-A1 | Nitrogenous Heterocyclic Compound and Pharmaceutical Use Thereof | MAPK1, MAPK13, MAPK6 | SLC22A12 1747/4885CREBBP 1296/4885ALDH1A1 2069/4885 |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | MAPK1, MAPK6, MAPK3 | SLC22A12 2397/4885CREBBP 1627/4885ALDH1A1 671/4885 |
| US-20100063104-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | NOS2, NOS1, MAPK1 | SLC22A12 697/4885CREBBP 1665/4885ALDH1A1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.